Aegerion Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Aegerion Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).
Aegerion Pharmaceuticals: 11 sponsored US clinical trials, none currently recruiting.
Aegerion Pharmaceuticals sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Homozygous Familial Hypercholesterolemia, with 1 trials.
Top-decile sponsor footprint
Aegerion Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
11 total, page 1 of 1
Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
NCT04026178
Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects
NCT02080468
Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.
NCT02080455
Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
NCT00943306
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
NCT00690443
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
NCT00730236
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
NCT00559962
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
NCT00474240
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
NCT00405067
Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents
NCT00359281
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
NCT01556906
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 6 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Therapeutic Areas
How the Aegerion Pharmaceuticals early-phase archive is shaped
11 indexed studies, none listed as recruiting (0% open); 11 completed (100%).
Phase mix: 3 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Homozygous Familial Hypercholesterolemia (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Aegerion Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Aegerion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 11 archived trials
- Aderans Research Institute · 11 trials · 0% recruiting
- Allena Pharmaceuticals · 11 trials · 0% recruiting
- AOBiome · 11 trials · 0% recruiting
- Armata Pharmaceuticals · 11 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Aegerion Pharmaceuticals page
11 registered trials is a research-attention snapshot, not an endorsement of Aegerion Pharmaceuticals or any single study.
- None of Aegerion Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Homozygous Familial Hypercholesterolemia is the condition Aegerion Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Homozygous Familial Hypercholesterolemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aegerion Pharmaceuticals pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.